Therapeutics Companies in Germany

We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

Who we are: atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. Our vision: To heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.

CUREosity is a multiple international award-winning Med-Tec company located in Düsseldorf, Germany, that is changing rehabilitation by developing innovative therapy concepts. With our vision to revolutionize traditional rehabilitation we develop VR-based therapy applications and games to help people with neurological and mental disabilities. Change the world and become part of a unique collaboration between scientists, medical doctors, therapists, software developers and game designers. Together we develop completely new motion therapy systems - immersive instead of invasive. Impairments we aim to heal include stroke, craniocerebral trauma, MS, cerebral palsy, Parkinson's, paraplegia as well as dementia, depression, anxiety and pain therapy. With CUREO we developed our first smart software solution for innovative VR therapy that can be used immediately in any clinic. Grow with us! Give your daily work a deeper meaning and support us with your talent to help people with neurological and psychological disabilities. You can also benefit from being on board by growing with us personally and professionally, revolutionizing traditional rehabilitation. Became curious? Then follow or contact us on LinkedIn, visit our website and apply at jobs@cureosity.de!

Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

Mindable Health offers a therapeutic app to overcome anxiety.

Orthopred in Wiesloch bietet regenerative Orthopädie mit modernen Therapien für mehr Beweglichkeit und zur Vermeidung unnötiger Operationen.